Vera Therapeutics director granted 17,084 stock options

Vera Therapeutics director Michael Morrissey received a grant of stock options covering 17,084 shares of Class A Common Stock.

Rhea-AI Filing Summary

Vera Therapeutics director Michael Morrissey received a grant of stock options covering 17,084 shares of Class A Common Stock. The options have a per-share exercise price of $34.35 and expire in 2036. They vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, with full vesting upon a change in control if he remains in service.

Insider Trade Summary

Grant/Award: 17,084 shares

Grant/Award 1 txn

Insider MORRISSEY MICHAEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,084	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,084 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Key Figures

Option grant size: 17,084 options Exercise price: $34.35 per share Underlying shares: 17,084 shares +3 more

6 metrics

Option grant size 17,084 options Stock Option (right to buy) granted to director

Exercise price $34.35 per share Conversion or exercise price of the options

Underlying shares 17,084 shares Class A Common Stock underlying the options

Post-grant derivative holdings 17,084 options Total derivative shares following transaction

Option expiration May 20, 2036 Expiration date of the stock options

Vesting end reference year 2027 Earlier of first anniversary or 2027 annual stockholder meeting

Key Terms

Stock Option (right to buy), Class A Common Stock, change in control, continuous service

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

change in control financial

"shares will vest in full upon a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vera Therapeutics (VERA) report for Michael Morrissey?

Vera Therapeutics reported that director Michael Morrissey received a grant of stock options covering 17,084 shares. These options are a compensation award, not an open-market purchase, and give him the right to buy Class A Common Stock at a fixed exercise price in the future.

What is the exercise price and expiration for Michael Morrissey’s Vera Therapeutics options?

The granted options have an exercise price of $34.35 per share and expire in 2036. This means Morrissey can choose to buy 17,084 shares at $34.35 any time before the May 20, 2036 expiration date, once the options have vested under the award terms.

How and when do Michael Morrissey’s Vera Therapeutics stock options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting. Vesting is conditioned on Morrissey’s continuous service, and all options also vest fully upon a change in control if he remains in service through that date.

Did Michael Morrissey buy or sell Vera Therapeutics shares in the open market?

No, this Form 4 reports a grant of stock options as compensation, not an open-market trade. The transaction code is “A,” described as a grant, award, or other acquisition, meaning he received options rather than buying or selling existing Vera Therapeutics shares on the market.

How many Vera Therapeutics shares are covered by Michael Morrissey’s new option grant?

The stock option grant covers 17,084 underlying shares of Vera Therapeutics Class A Common Stock. Following this grant, Morrissey holds options on 17,084 shares directly, giving him the right, once vested, to purchase that number of shares at the fixed exercise price of $34.35.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORRISSEY MICHAEL

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.35	05/21/2026		A		17,084		(1)	05/20/2036	Class A Common Stock	17,084	$0	17,084	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

	/s/ Joseph R. Young, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)